An epigenetic signature in CD19-CAR T cells predicts clinical outcome

Simonetta, Federico; Bertoni, Francesco

doi:10.1016/j.trecan.2021.12.005

Article scientifique

Anglais

An epigenetic signature in CD19-CAR T cells predicts clinical outcome

Contributeurs/tricesSimonetta, Federico; Bertoni, Francesco

Publié dansTrends in cancer, vol. 8, no. 2, p. 81-82

Date de publication2022-02

Date de mise en ligne2021-12-28

Résumé

The potential impact of epigenetic profiles on adoptive T cell immunotherapies is currently unknown. In a recent study in the Journal of the National Cancer Institute, Garcia-Prieto et al. show that specific DNA methylation profiles of CD19-CAR T cells are associated with improved clinical outcome of patients with B cell malignancies.

Mots-clés

CAR T cells
Biomarker
Leukemia
Lymphoma
Methylation
Resistance

Structure d'affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Groupe de recherche

Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)

Citation (format ISO)

SIMONETTA, Federico, BERTONI, Francesco. An epigenetic signature in CD19-CAR T cells predicts clinical outcome. In: Trends in cancer, 2022, vol. 8, n° 2, p. 81–82. doi: 10.1016/j.trecan.2021.12.005

Article (Published version)

Identifiants

PID : unige:163868
DOI : 10.1016/j.trecan.2021.12.005
PMID : 34972674

ISSN du journal2405-8025

111vues

0téléchargements

Création22/03/2022 12:45:00

Première validation22/03/2022 12:45:00

Heure de mise à jour16/03/2023 07:43:48

Changement de statut16/03/2023 07:43:47

Dernière indexation01/02/2024 08:53:11

Archive ouverte UNIGE

An epigenetic signature in CD19-CAR T cells predicts clinical outcome

Informations techniques